Please enable JavaScript to continue using this application.

Compare $EBS vs $ENTA | Chartloom

Compare

$EBS vs $ENTA

Emergent BioSolutions Inc · Enanta Pharmaceuticals Inc

EBS

Emergent BioSolutions Inc

ENTA

Enanta Pharmaceuticals Inc

Compare $EBS vs $ENTA

Comparing Emergent BioSolutions Inc and Enanta Pharmaceuticals Inc

EBSEmergent BioSolutions Inc

ENTAEnanta Pharmaceuticals Inc

EBSEmergent BioSolutions Inc

Market cap

$364M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-9.6%

YTD performance

-43.6%

52W performance

-28.6%

FCF yield

9.7%

ENTAEnanta Pharmaceuticals Inc

Market cap

$364M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.51x

Rev growth (TTM)

0.7%

YTD performance

-13.3%

52W performance

10.6%

FCF yield

-10.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

EBS

ENTA

Detailed metrics comparison

EBS

Emergent BioSolutions Inc

ENTA

Enanta Pharmaceuticals Inc

Market Cap

EBS$364M

ENTA$364M

Enterprise Value

EBS$806M

ENTA$456M

Price

EBS$7.06

ENTA$12.50

P/E Ratio

EBSN/A

ENTAN/A

P/S Ratio

EBS0.47x

ENTA5.57x

EV/Sales

EBS1.05x

ENTA6.99x

EV/EBITDA

EBS3.65x

ENTA31.83x

P/B Ratio

EBS0.95x

ENTA3.73x

P/FCF Ratio

EBS10.26x

ENTAN/A

EV/FCF

EBS22.72x

ENTA-12.36x

PEG Ratio

EBSN/A

ENTAN/A

Forward P/E (NTM)

EBSN/A

ENTAN/A

Forward P/S (NTM)

EBSN/A

ENTA6.51x

Revenue (TTM)

EBS$770M

ENTA$65M

Revenue Growth (YoY)

EBS-9.6%

ENTA0.7%

Forward Rev Growth

EBS7.1%

ENTA-7.3%

Gross Margin (TTM)

EBS55.8%

ENTA0.0%

Operating Margin (TTM)

EBS0.0%

ENTA0.0%

EBITDA Margin (TTM)

EBS28.7%

ENTA-82.5%

Net Margin (TTM)

EBS-23.0%

ENTA-96.9%

FCF Margin (TTM)

EBS4.6%

ENTA-56.6%

Net Income (TTM)

EBS$-177M

ENTA$-63M

FCF (TTM)

EBS$36M

ENTA$-37M

EPS (TTM)

EBS-$3.43

ENTA-$2.17

ROE (TTM)

EBS-3591.0%

ENTA-6184.0%

ROA (TTM)

EBS-1356.0%

ENTA-2070.0%

ROIC (TTM)

EBS-1622.0%

ENTA-2677.0%

Cash

EBS$140M

ENTA$33M

Debt

EBS$582M

ENTA$126M

Net Cash/Debt

EBS$-442M

ENTA$-93M

Current Ratio (TTM)

EBS5.42x

ENTA3.76x

Quick Ratio (TTM)

EBS2.74x

ENTA3.62x

Debt/Equity (TTM)

EBS1.70x

ENTA1.25x

Debt/Assets (TTM)

EBS0.0%

ENTA0.0%

Interest Coverage (TTM)

EBSN/A

ENTAN/A

Net Debt/EBITDA (TTM)

EBS0.00x

ENTA0.00x

Beta

EBS2.42

ENTA0.72

52W Performance

EBS-28.6%

ENTA10.6%

YTD Performance

EBS-43.6%

ENTA-13.3%

% from 52W High

EBS-49.8%

ENTA-27.1%

% from 52W Low

EBS61.9%

ENTA22.5%

Asset Turnover (TTM)

EBS0.59x

ENTA0.21x

FCF Yield (TTM)

EBS9.7%

ENTA-10.2%

Earnings Yield (TTM)

EBS-48.5%

ENTA-17.4%

Dividend Yield (TTM)

EBSN/A

ENTAN/A

Rule of 40

EBS-4.9

ENTA-55.9

EV/GP/RG

EBS0.27

ENTAN/A

Ticker research

View EBS research View ENTA research

Metric	EBS Emergent BioSolutions Inc	ENTA Enanta Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$364M
Enterprise Value	$806M	$456M
Price	$7.06	$12.50
P/E Ratio	N/A	N/A
P/S Ratio	0.47x	5.57x
EV/Sales	1.05x	6.99x
EV/EBITDA	3.65x	31.83x
P/B Ratio	0.95x	3.73x
P/FCF Ratio	10.26x	N/A
EV/FCF	22.72x	-12.36x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	6.51x
Revenue & Growth
Revenue (TTM)	$770M	$65M
Revenue Growth (YoY)	-9.6%	0.7%
Forward Rev Growth	7.1%	-7.3%
Profitability
Gross Margin (TTM)	55.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	28.7%	-82.5%
Net Margin (TTM)	-23.0%	-96.9%
FCF Margin (TTM)	4.6%	-56.6%
Net Income (TTM)	$-177M	$-63M
FCF (TTM)	$36M	$-37M
EPS (TTM)	-$3.43	-$2.17
ROE (TTM)	-3591.0%	-6184.0%
ROA (TTM)	-1356.0%	-2070.0%
ROIC (TTM)	-1622.0%	-2677.0%
Financial Health
Cash	$140M	$33M
Debt	$582M	$126M
Net Cash/Debt	$-442M	$-93M
Current Ratio (TTM)	5.42x	3.76x
Quick Ratio (TTM)	2.74x	3.62x
Debt/Equity (TTM)	1.70x	1.25x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.42	0.72
52W Performance	-28.6%	10.6%
YTD Performance	-43.6%	-13.3%
% from 52W High	-49.8%	-27.1%
% from 52W Low	61.9%	22.5%
Efficiency & Yields
Asset Turnover (TTM)	0.59x	0.21x
FCF Yield (TTM)	9.7%	-10.2%
Earnings Yield (TTM)	-48.5%	-17.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	-55.9
EV/GP/RG	0.27	N/A
Ticker research	View EBS research	View ENTA research

Valuation

P/S Ratio

EBS

0.47x

ENTA

5.57x

EV/FCF

ENTA

-12.36x

EBS

22.72x

Growth & revenue

Revenue Growth TTM

ENTA

0.7%

EBS

-9.6%

Forward Revenue Growth

EBS

7.1%

ENTA

-7.3%

Profitability & performance

Gross Margin

EBS

55.8%

ENTA

0.0%

ROE

EBS

-3591.0%

ENTA

-6184.0%

FCF Yield %

EBS

9.7%

ENTA

-10.2%

52-Week Performance

ENTA

10.6%

EBS

-28.6%

Detailed metrics comparison

EBS

Emergent BioSolutions Inc

ENTA

Enanta Pharmaceuticals Inc

Market Cap

EBS$364M

ENTA$364M

Enterprise Value

EBS$806M

ENTA$456M

Price

EBS$7.06

ENTA$12.50

P/E Ratio

EBSN/A

ENTAN/A

P/S Ratio

EBS0.47x

ENTA5.57x

EV/Sales

EBS1.05x

ENTA6.99x

EV/EBITDA

EBS3.65x

ENTA31.83x

P/B Ratio

EBS0.95x

ENTA3.73x

P/FCF Ratio

EBS10.26x

ENTAN/A

EV/FCF

EBS22.72x

ENTA-12.36x

PEG Ratio

EBSN/A

ENTAN/A

Forward P/E (NTM)

EBSN/A

ENTAN/A

Forward P/S (NTM)

EBSN/A

ENTA6.51x

Revenue (TTM)

EBS$770M

ENTA$65M

Revenue Growth (YoY)

EBS-9.6%

ENTA0.7%

Forward Rev Growth

EBS7.1%

ENTA-7.3%

Gross Margin (TTM)

EBS55.8%

ENTA0.0%

Operating Margin (TTM)

EBS0.0%

ENTA0.0%

EBITDA Margin (TTM)

EBS28.7%

ENTA-82.5%

Net Margin (TTM)

EBS-23.0%

ENTA-96.9%

FCF Margin (TTM)

EBS4.6%

ENTA-56.6%

Net Income (TTM)

EBS$-177M

ENTA$-63M

FCF (TTM)

EBS$36M

ENTA$-37M

EPS (TTM)

EBS-$3.43

ENTA-$2.17

ROE (TTM)

EBS-3591.0%

ENTA-6184.0%

ROA (TTM)

EBS-1356.0%

ENTA-2070.0%

ROIC (TTM)

EBS-1622.0%

ENTA-2677.0%

Cash

EBS$140M

ENTA$33M

Debt

EBS$582M

ENTA$126M

Net Cash/Debt

EBS$-442M

ENTA$-93M

Current Ratio (TTM)

EBS5.42x

ENTA3.76x

Quick Ratio (TTM)

EBS2.74x

ENTA3.62x

Debt/Equity (TTM)

EBS1.70x

ENTA1.25x

Debt/Assets (TTM)

EBS0.0%

ENTA0.0%

Interest Coverage (TTM)

EBSN/A

ENTAN/A

Net Debt/EBITDA (TTM)

EBS0.00x

ENTA0.00x

Beta

EBS2.42

ENTA0.72

52W Performance

EBS-28.6%

ENTA10.6%

YTD Performance

EBS-43.6%

ENTA-13.3%

% from 52W High

EBS-49.8%

ENTA-27.1%

% from 52W Low

EBS61.9%

ENTA22.5%

Asset Turnover (TTM)

EBS0.59x

ENTA0.21x

FCF Yield (TTM)

EBS9.7%

ENTA-10.2%

Earnings Yield (TTM)

EBS-48.5%

ENTA-17.4%

Dividend Yield (TTM)

EBSN/A

ENTAN/A

Rule of 40

EBS-4.9

ENTA-55.9

EV/GP/RG

EBS0.27

ENTAN/A

Ticker research

View EBS research View ENTA research

Metric	EBS Emergent BioSolutions Inc	ENTA Enanta Pharmaceuticals Inc
Market & Valuation
Market Cap	$364M	$364M
Enterprise Value	$806M	$456M
Price	$7.06	$12.50
P/E Ratio	N/A	N/A
P/S Ratio	0.47x	5.57x
EV/Sales	1.05x	6.99x
EV/EBITDA	3.65x	31.83x
P/B Ratio	0.95x	3.73x
P/FCF Ratio	10.26x	N/A
EV/FCF	22.72x	-12.36x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	6.51x
Revenue & Growth
Revenue (TTM)	$770M	$65M
Revenue Growth (YoY)	-9.6%	0.7%
Forward Rev Growth	7.1%	-7.3%
Profitability
Gross Margin (TTM)	55.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	28.7%	-82.5%
Net Margin (TTM)	-23.0%	-96.9%
FCF Margin (TTM)	4.6%	-56.6%
Net Income (TTM)	$-177M	$-63M
FCF (TTM)	$36M	$-37M
EPS (TTM)	-$3.43	-$2.17
ROE (TTM)	-3591.0%	-6184.0%
ROA (TTM)	-1356.0%	-2070.0%
ROIC (TTM)	-1622.0%	-2677.0%
Financial Health
Cash	$140M	$33M
Debt	$582M	$126M
Net Cash/Debt	$-442M	$-93M
Current Ratio (TTM)	5.42x	3.76x
Quick Ratio (TTM)	2.74x	3.62x
Debt/Equity (TTM)	1.70x	1.25x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.42	0.72
52W Performance	-28.6%	10.6%
YTD Performance	-43.6%	-13.3%
% from 52W High	-49.8%	-27.1%
% from 52W Low	61.9%	22.5%
Efficiency & Yields
Asset Turnover (TTM)	0.59x	0.21x
FCF Yield (TTM)	9.7%	-10.2%
Earnings Yield (TTM)	-48.5%	-17.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	-55.9
EV/GP/RG	0.27	N/A
Ticker research	View EBS research	View ENTA research